Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy
- PMID: 19040993
- DOI: 10.1016/j.surg.2008.08.037
Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy
Abstract
Background: Hepatic metastases from neuroendocrine cancer dramatically reduce survival, introducing an important opportunity for intervention. Several treatment modalities have been examined, but an optimal treatment approach has been difficult to define. We evaluated a regimen combining hepatic artery chemoinfusion with chemoembolization.
Methods: Patients with neuroendocrine cancer and diffuse hepatic metastases were treated with hepatic artery chemoinfusion and chemoembolization when they demonstrated disease progression despite octreotide therapy. Four monthly cycles of 5-fluorouracil were administered via hepatic artery infusion with chemoembolization after the final 2 cycles. Response was defined by radiologic response or symptomatic improvement.
Results: Seventy-seven patients were treated; 18 received chemoinfusion only. The treatment-related mortality rate was 7%. The overall response rate was 80% for patients with carcinoid or islet cell neoplasms. Median progression-free survival was 19 months. Median disease-specific survival was 39 months from the first treatment; 1- and 5-year survival rates were 78% and 27%, respectively.
Conclusion: Survival after initiating this regimen was over 3 years for the majority of patients exhibiting progression of extensive, unresectable hepatic disease despite octreotide therapy. The addition of hepatic artery chemoinfusion to chemoembolization offers a high probability of clinical benefit to patients who, otherwise, have severely limited therapeutic options and a dismal survival.
Comment in
-
Treatment options for metastatic neuroendocrine tumors.Surgery. 2008 Dec;144(6):895-8. doi: 10.1016/j.surg.2008.10.003. Surgery. 2008. PMID: 19040994 No abstract available.
Similar articles
-
Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.Cancer. 2005 Oct 15;104(8):1590-602. doi: 10.1002/cncr.21389. Cancer. 2005. PMID: 16134179
-
Metastatic neuroendocrine hepatic tumors: resection improves survival.Arch Surg. 2006 Oct;141(10):1000-4; discussion 1005. doi: 10.1001/archsurg.141.10.1000. Arch Surg. 2006. PMID: 17043278
-
Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.Am J Clin Oncol. 2009 Dec;32(6):574-81. doi: 10.1097/COC.0b013e31819cca35. Am J Clin Oncol. 2009. PMID: 19636238
-
Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumours.Ital J Gastroenterol Hepatol. 1999 Oct;31 Suppl 2:S213-5. Ital J Gastroenterol Hepatol. 1999. PMID: 10604133 Review.
-
Therapeutic alternatives in metastatic neuroendocrine tumors.Surg Oncol Clin N Am. 1998 Oct;7(4):863-79. Surg Oncol Clin N Am. 1998. PMID: 9735138 Review.
Cited by
-
[Current views on the treatment of insulinoma].Probl Endokrinol (Mosk). 2024 Feb 28;70(1):46-55. doi: 10.14341/probl13281. Probl Endokrinol (Mosk). 2024. PMID: 38433541 Free PMC article. Review. Russian.
-
Defining a New Classification System for the Surgical Management of Neuroendocrine Tumor Liver Metastases.J Clin Med. 2023 Mar 23;12(7):2456. doi: 10.3390/jcm12072456. J Clin Med. 2023. PMID: 37048539 Free PMC article. Review.
-
The Role of Interventional Radiology for the Treatment of Hepatic Metastases from Neuroendocrine Tumor: An Updated Review.J Clin Med. 2020 Jul 20;9(7):2302. doi: 10.3390/jcm9072302. J Clin Med. 2020. PMID: 32698459 Free PMC article. Review.
-
Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors.J Clin Med. 2019 Nov 7;8(11):1907. doi: 10.3390/jcm8111907. J Clin Med. 2019. PMID: 31703375 Free PMC article. Review.
-
Treatment options for PNET liver metastases: a systematic review.World J Surg Oncol. 2018 Jul 14;16(1):142. doi: 10.1186/s12957-018-1446-y. World J Surg Oncol. 2018. PMID: 30007406 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical